The key products and services being delivered under this federal contract IDV award are Oxervate, an ophthalmic solution used to treat neurotrophic keratitis. The prime contractor, Dompe U.S. Inc., a foreign-owned for-profit pharmaceutical manufacturer, has received multiple contract vehicles from the Department of Veterans Affairs (VA) to provide Oxervate and other pharmaceutical products to VA healthcare facilities nationwide. This includes a single-award $2.4 million Blanket Purchase Agreement (BPA) from the VA National Acquisition Center, as well as a $5 million Federal Supply Schedule (FSS) contract and a previous $10 million BPA.
The VA has used these contract vehicles to issue firm fixed-price delivery orders to Dompe to fulfill urgent medication needs at VA facilities, including during the COVID-19 pandemic response. The delivery orders, valued up to $159,096.48, were placed against Dompe's GSA Pharmaceuticals and Drugs schedule contract (FSS-61-IB) without any set-aside designations. These contracts enable Dompe to continue supplying critical ophthalmic and pharmaceutical solutions to meet the healthcare needs of veterans served by the VA's regional Integrated Service Networks across the country.
Generated 2/27/25, 12:18 PM